Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
We have used patient-specific stem cell technology to uncover a surprising interplay between gain- and loss-of-function disease mechanisms in the most common form of ALS and FTD, caused by a repeat expansion mutation in C9ORF72. In addition, we have used high-throughput chemical screens on patient-derived neurons to identify novel therapeutic targets for C9ORF72 and sporadic ALS. Recently, we have developed a systematic approach for the identification of gene variants that cause sporadic ALS and are using it to investigate potential new ALS genes with key roles in proteostasis.
